Author

L. J. Esserman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

C. Yau· 2 shared A. D. Borowsky· 1 shared A. Glencer· 1 shared A. Goga· 1 shared A. Navickas· 1 shared A. Officer· 1 shared B. Hanisch· 1 shared B. J. Woo· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Yau

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers

J. Wang, J. M. Suh, B. J. Woo, A. Navickas, K. Garcia, K. Yin, L. Fish, T. Cavazos, B. Hanisch, D. Markett, S. Yu, G. Hirst, L. Brown-Swigart, L. J. Esserman, L. J. van 't Veer, H. Goodarzi

The paper systematically identifies and characterizes cancer-emergent oncRNAs across 32 tumor types, showing they act as blood-accessible molecular barcodes for cancer identity and prognosis.

bioRxiv · Mar 19, 2024Cancer Biology

Tumor microenvironmental determinants of high-risk DCIS progression

A. Glencer, K. Ramalingam, N. Schindler, H. Mori, P. Ghule, K. C. Lee, D. Nachmanson, A. Officer, O. Harismendy, J. L. Stein, G. Stein, D. Weaver, C. Yau, G. L. Hirst, M. J. Campbell, , A. D. Borowsky

This study identifies immune microenvironment features and myoepithelial continuity as key determinants of progression in high-risk DCIS.

bioRxiv · Dec 1, 2023 · PreprintCancer Biology

Combinatorial immunotherapies overcome MYC-driven immune evasion

J. V. Lee, F. Houseley, C. Yau, D. Van de Mark, R. Nakagawa, G. Hemmati, G. A. Hernandez, J. Winkler, Y. Zhang, S. Samson, C. Baas, L. J. Esserman, L. J. Van't Veer, H. S. Rugo, M. Matloubian, A. Goga

This study shows that MYC-driven immune evasion in TNBC can be reversed by combining immunotherapies, leading to tumor regression in mice.

bioRxiv · May 7, 2021Cancer Biology